Home › Ventricular Tachycardia › NCT06743789
Trial in Arrhythmia Radioablation for Ventricular Tachycardia: Single Fraction vs Three Fractions
Dose De-escalation Randomized Phase I/II Trial in Arrhythmia Radioablation for Ventricular Tachycardia: Single Fraction vs Three Fractions
Who can join
Ages 18 to 90 · All sexes
Full eligibility criteria
Inclusion Criteria: * Age ≥ 18 years * Structural heart disease: 1. Ischemic cardiomyopathy 2. Non-ischemic cardiomyopathy 3. Hypertrophic cardiomyopathy * Refractory VT severity: 1. VT leading to ICD shock with minimum 3 episodes in any 3-month period without reversible cause; 2. Failed or intolerant to antiarrhythmic drug therapy (either amiodarone or ≥ 2 AADs) AND failed ablation (CA) 3. OR ablation (CA) contraindicated * Ability to understand study protocol and to write informed consent * Willing to comply with specified pre-, post- and follow-up testing, evaluations and requirements * Expected to remain available for at least 36 months after enrollment Exclusion Criteria: * Age \< 18 years * Pregnancy * Prior chest radiation therapy
About the study
This is a research study that aims to understand if giving a lower dose of treatment all at once is as effective and safe as dividing it into three smaller doses for patients with a heart condition called refractory ventricular tachycardia (VT). These patients have not exhibited positive responses to conventional medications or procedures. This study aims to explore whether an alternative approach could yield more beneficial outcomes.
What is being tested
- Radiation Therapy (radiation)
- Radiation Therapy (radiation)
- Radiation Therapy (radiation)
- Radiation Therapy (radiation)
- Radiation Therapy (radiation)
- Radiation Therapy (radiation)
Sponsor: Weill Medical College of Cornell University · Participants: 40 · Started: Dec 18, 2024
Contact the study team
- Fabiana Gregucci, M.D. · Phone: 646 962 3110
- Fereshteh Talebi, M.D. · Phone: 646 702 7830
Official record on ClinicalTrials.gov — NCT06743789
Locations in the U.S.
| New York | Weill Cornell Medicine, New York |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.